MESO saw its Momentum Indicator move above the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In 79 of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at 84%.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MESO's RSI Indicator exited the oversold zone, 19 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The Moving Average Convergence Divergence (MACD) for MESO just turned positive on October 28, 2026. Looking at past instances where MESO's MACD turned positive, the stock continued to rise in 36 of 47 cases over the following month. The odds of a continued upward trend are 77%.
The 10-day moving average for MESO crossed bullishly above the 50-day moving average on November 11, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where MESO advanced for three days, in 232 of 279 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
MESO moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MESO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
MESO broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MESO entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 69 (best 1 - 100 worst), indicating slightly worse than average price growth. MESO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 87 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MESO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.260) is normal, around the industry mean (3.498). P/E Ratio (-32.140) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (29.240) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (15.504) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
TRAW saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 07, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 38 instances where the indicator turned negative. In 35 of the 38 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on October 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TRAW as a result. In 72 of 81 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The 10-day moving average for TRAW crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TRAW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TRAW entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TRAW's RSI Indicator exited the oversold zone, 37 of 49 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +8.99% 3-day Advance, the price is estimated to grow further. Considering data from situations where TRAW advanced for three days, in 177 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
TRAW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.017) is normal, around the industry mean (3.498). P/E Ratio (-0.121) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.824) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. TRAW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TRAW’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MESO | TRAW | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 9 | 51 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 94 Overvalued | 66 Overvalued | |
PROFIT vs RISK RATING 1..100 | 87 | 100 | |
SMR RATING 1..100 | 94 | 100 | |
PRICE GROWTH RATING 1..100 | 69 | 95 | |
P/E GROWTH RATING 1..100 | 27 | 98 | |
SEASONALITY SCORE 1..100 | 50 | 45 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TRAW's Valuation (66) in the Biotechnology industry is in the same range as MESO (94). This means that TRAW’s stock grew similarly to MESO’s over the last 12 months.
MESO's Profit vs Risk Rating (87) in the Biotechnology industry is in the same range as TRAW (100). This means that MESO’s stock grew similarly to TRAW’s over the last 12 months.
MESO's SMR Rating (94) in the Biotechnology industry is in the same range as TRAW (100). This means that MESO’s stock grew similarly to TRAW’s over the last 12 months.
MESO's Price Growth Rating (69) in the Biotechnology industry is in the same range as TRAW (95). This means that MESO’s stock grew similarly to TRAW’s over the last 12 months.
MESO's P/E Growth Rating (27) in the Biotechnology industry is significantly better than the same rating for TRAW (98). This means that MESO’s stock grew significantly faster than TRAW’s over the last 12 months.
| MESO | TRAW | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 76% | 1 day ago 76% |
| Stochastic ODDS (%) | 1 day ago 80% | 1 day ago 85% |
| Momentum ODDS (%) | 1 day ago 84% | 6 days ago 89% |
| MACD ODDS (%) | 1 day ago 77% | 6 days ago 90% |
| TrendWeek ODDS (%) | 1 day ago 83% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 79% | 1 day ago 90% |
| Advances ODDS (%) | 3 days ago 83% | 3 days ago 80% |
| Declines ODDS (%) | 1 day ago 84% | 7 days ago 90% |
| BollingerBands ODDS (%) | 1 day ago 86% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 80% | 1 day ago 89% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MESO’s FA Score shows that 1 FA rating(s) are green while TRAW’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MESO’s TA Score shows that 4 TA indicator(s) are bullish while TRAW’s TA Score has 4 bullish TA indicator(s).
MESO (@Biotechnology) experienced а -5.28% price change this week, while TRAW (@Biotechnology) price change was -7.41% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
MESO is expected to report earnings on Nov 25, 2026.
TRAW is expected to report earnings on Nov 12, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, MESO has been loosely correlated with QTTB. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MESO jumps, then QTTB could also see price increases.
| Ticker / NAME | Correlation To MESO | 1D Price Change % | ||
|---|---|---|---|---|
| MESO | 100% | -2.43% | ||
| QTTB - MESO | 51% Loosely correlated | -1.39% | ||
| SRPT - MESO | 38% Loosely correlated | +1.58% | ||
| MIST - MESO | 33% Poorly correlated | N/A | ||
| TNGX - MESO | 33% Poorly correlated | +5.88% | ||
| TRAW - MESO | 31% Poorly correlated | +11.11% | ||
More | ||||
A.I.dvisor indicates that over the last year, TRAW has been loosely correlated with SLGL. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if TRAW jumps, then SLGL could also see price increases.
| Ticker / NAME | Correlation To TRAW | 1D Price Change % | ||
|---|---|---|---|---|
| TRAW | 100% | +11.11% | ||
| SLGL - TRAW | 47% Loosely correlated | +3.09% | ||
| MESO - TRAW | 34% Loosely correlated | -2.43% | ||
| ELTX - TRAW | 33% Loosely correlated | +1.24% | ||
| TAOX - TRAW | 32% Poorly correlated | -1.55% | ||
| AXON - TRAW | 32% Poorly correlated | +4.26% | ||
More | ||||